| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bettina Konte, James T R Walters, Dan Rujescu, Sophie E Legge, Antonio F Pardiñas, Dan Cohen, Munir Pirmohamed, Jari Tiihonen, Annette M Hartmann, Jan P Bogers, Jan van der Weide, Karen van der Weide, Anu Putkonen, Eila Repo-Tiihonen, Tero Hallikainen, Ed Silva, Oddur Ingimarsson, Engilbert Sigurdsson, James L Kennedy, Patrick F Sullivan, Marcella Rietschel, Gerome Breen, Hreinn Stefansson, Kari Stefansson, David A Collier, Michael C O'Donovan, Ina Gieglin. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational psychiatry. vol 11. issue 1. 2021-06-28. PMID:33846298. |
the atypical antipsychotic clozapine is the only effective medication for treatment-resistant schizophrenia. |
2021-06-28 |
2023-08-13 |
Not clear |
| Claudio Ciprian, Kirill Masychev, Maryam Ravan, James P Reilly, Duncan Maccrimmo. A Machine Learning Approach Using Effective Connectivity to Predict Response to Clozapine Treatment. IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society. vol 28. issue 12. 2021-06-24. PMID:33513093. |
clozapine is an anti-psychotic drug that is known to be effective in the treatment of patients with chronic treatment-resistant schizophrenia (trs-scz), commonly estimated to be around one third of all cases. |
2021-06-24 |
2023-08-13 |
Not clear |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. |
2021-06-23 |
2023-08-13 |
human |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
this study investigated subcortical morphometric changes 6 months after switching treatment to clozapine in patients with treatment-resistant schizophrenia compared with healthy volunteers, and the relationships between longitudinal volume changes and clinical variables. |
2021-06-23 |
2023-08-13 |
human |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
in total, 1.5t mri images were acquired at baseline before commencing clozapine and again after 6 months of treatment for 33 patients with treatment-resistant schizophrenia and 31 controls, and processed using the longitudinal pipeline of freesurfer v.5.3.0. |
2021-06-23 |
2023-08-13 |
human |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
patients with treatment-resistant schizophrenia display progressive subcortical volume deficits after switching to clozapine despite experiencing symptomatic improvement. |
2021-06-23 |
2023-08-13 |
human |
| Kohei Kitagawa, Shusuke Uekusa, Kazuhiro Matsuo, Kei Moriyama, Tatsuro Yamamoto, Yuji Yada, Masafumi Kodama, Yoshiki Kishi, Takashi Yoshi. Risk factors for clozapine-induced central nervous system abnormalities in Japanese patients with treatment-resistant schizophrenia. Asian journal of psychiatry. vol 60. 2021-06-21. PMID:33866283. |
we retrospectively analyzed data from 106 patients with schizophrenia who received clozapine treatment through our hospital. |
2021-06-21 |
2023-08-13 |
Not clear |
| Neslyne B Augustin, Michael Maroule. Hyperleukocytosis during clozapine treatment: A rare presentation of B-cell Acute lymphoblastic leukemia. Leukemia research reports. vol 15. 2021-06-19. PMID:34141565. |
clozapine has been widely used as an antipsychotic drug for the treatment of refractory schizophrenia. |
2021-06-19 |
2023-08-13 |
Not clear |
| Neslyne B Augustin, Michael Maroule. Hyperleukocytosis during clozapine treatment: A rare presentation of B-cell Acute lymphoblastic leukemia. Leukemia research reports. vol 15. 2021-06-19. PMID:34141565. |
we report the case of a 31-year-old patient who developed acute lymphoblastic leukemia shortly after starting treatment with clozapine for refractory schizophrenia. |
2021-06-19 |
2023-08-13 |
Not clear |
| Rocco F Marotta, Frank D Buono, Amir Garakani, Eric Collins, Brianna Cerrito, David Rowe David Row. The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 32. issue 2. 2021-06-18. PMID:32343282. |
the effects of augmenting clozapine with oxytocin in schizophrenia: an initial case series. |
2021-06-18 |
2023-08-13 |
Not clear |
| Nian Liu, Yuan Xiao, Wenjing Zhang, Biqiu Tang, Jiaxin Zeng, Na Hu, Shah Chandan, Qiyong Gong, Su Lu. Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients. Translational psychiatry. vol 10. issue 1. 2021-06-18. PMID:32398765. |
to explore the different patterns of gray matter alterations among chronic never treated patients and those treated with monotherapy, we recruited 35 never-treated chronic schizophrenia patients with illness durations ranging from 5 to 48 years, 20 illness duration-matched risperidone monotherapy and 20 clozapine monotherapy patients, and 55 healthy controls. |
2021-06-18 |
2023-08-13 |
Not clear |
| Robert Løvsletten Smith, Kevin O'Connell, Lavinia Athanasiu, Srdjan Djurovic, Marianne Kristiansen Kringen, Ole A Andreassen, Espen Molde. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. Translational psychiatry. vol 10. issue 1. 2021-06-18. PMID:32555152. |
identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. |
2021-06-18 |
2023-08-13 |
Not clear |
| Bruno B Ortiz, Cinthia H Higuchi, Cristiano Noto, Dan W Joyce, Christoph U Correll, Rodrigo A Bressan, Ary Gadelh. A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice. Schizophrenia research. vol 218. 2021-06-17. PMID:31956005. |
early identification of symptoms that can predict treatment-resistant schizophrenia (trs) could help clinicians to avoid delays in clozapine therapy. |
2021-06-17 |
2023-08-13 |
Not clear |
| Meha Verma, Swapnajeet Sahoo, Ritu Nehra, Sandeep Grove. Does clozapine improves cognition in patients with treatment resistant schizophrenia?: An exploratory study. Schizophrenia research. vol 218. 2021-06-17. PMID:32063439. |
does clozapine improves cognition in patients with treatment resistant schizophrenia? |
2021-06-17 |
2023-08-13 |
Not clear |
| Georgios Schoretsanitis, Alan Mendelowitz, Chitra Malur, Raphael J Braga, Nina R Schooler, Majnu John, Jose de Leon, John M Kane, Georgios Petride. Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia research. vol 218. 2021-06-17. PMID:32107101. |
lack of ect effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: pharmacokinetic evidence from a randomized clinical trial. |
2021-06-17 |
2023-08-13 |
Not clear |
| Susanna Every-Palmer, Stephen J Inns, Pete M Elli. Constipation screening in people taking clozapine: A diagnostic accuracy study. Schizophrenia research. vol 220. 2021-06-17. PMID:32245597. |
clozapine is the favoured antipsychotic for treatment-refractory schizophrenia but its safe use requires careful adverse-effect management. |
2021-06-17 |
2023-08-13 |
Not clear |
| Eric Kelleher, Patricia McNamara, Jean Dunne, Brian Fitzmaurice, Elizabeth A Heron, Peter Whitty, Richard Walsh, Christina Mooney, Denise Hogan, Niall Conlon, Michael Gill, Angela Vincent, Colin P Doherty, Aiden Corvi. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia research. vol 222. 2021-06-17. PMID:32499165. |
prevalence of n-methyl-d-aspartate receptor antibody (nmdar-ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. |
2021-06-17 |
2023-08-13 |
Not clear |
| Eric Kelleher, Patricia McNamara, Jean Dunne, Brian Fitzmaurice, Elizabeth A Heron, Peter Whitty, Richard Walsh, Christina Mooney, Denise Hogan, Niall Conlon, Michael Gill, Angela Vincent, Colin P Doherty, Aiden Corvi. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia research. vol 222. 2021-06-17. PMID:32499165. |
we aimed to examine the prevalence of nmdar-ab encephalitis in patients with first episode psychosis (fep) and treatment resistant schizophrenia (trs) on clozapine, using clinical investigations, antibody testing and to retrospectively apply diagnostic consensus criteria. |
2021-06-17 |
2023-08-13 |
Not clear |
| Kirill Masychev, Claudio Ciprian, Maryam Ravan, Akshaya Manimaran, AnkitaAmol Deshmuk. Quantitative biomarkers to predict response to clozapine treatment using resting EEG data. Schizophrenia research. vol 223. 2021-06-17. PMID:32928617. |
clozapine is an anti-psychotic drug that is known to be effective in the treatment of patients with chronic treatment-resistant schizophrenia (trs-scz), commonly estimated to be around one third of all cases. |
2021-06-17 |
2023-08-13 |
Not clear |
| Mattia Campana, Peter Falkai, Dan Siskind, Alkomiet Hasan, Elias Wagne. Characteristics and definitions of ultra-treatment-resistant schizophrenia - A systematic review and meta-analysis. Schizophrenia research. vol 228. 2021-06-17. PMID:33454644. |
the aim of this systematic review and meta-analysis was to characterize ultra-treatment-resistant schizophrenia also known as clozapine-resistant schizophrenia (crs) patients across clozapine combination and augmentation trials through demographic and clinical baseline data. |
2021-06-17 |
2023-08-13 |
Not clear |